Evidence map›Paper›PMID 41716471›Full record

ArticleMolecular therapy. Oncology2026

A comparative analysis of CD70-directed CAR-T cells for glioblastoma treatment demonstrates a superior efficacy of the ligand-based construct.

Alexandros Kourtesakis, Hiu Nam Hannah Chow, Eileen Bailey, Sandra Horschitz, Ammar Jabali, Rainer Will, Christoph Schifflers, Abigail K Suwala, Hannah Rohdjess, Melissa Hahn and 21 more

Abstract read
In one paragraph

Article in Molecular therapy. Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Alexandros KourtesakisClinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Hiu Nam Hannah ChowClinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Eileen BaileyClinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Sandra HorschitzCentral Institute of Mental Health, 68159 Mannheim, Germany.
Ammar JabaliCentral Institute of Mental Health, 68159 Mannheim, Germany.
Rainer WillCore Facility Cellular Tools, DKFZ German Cancer Research Center, 69120 Heidelberg, Germany.
Christoph SchifflersImmunotherapy and Immunoprevention, DKFZ German Cancer Research Center, 69120 Heidelberg, Germany.
Abigail K SuwalaGerman Cancer Research Center (DKFZ), German Consortium for Translational Cancer Research (DKTK), Clinical Cooperation Unit Neuropathology, 69120 Heidelberg, Germany.
Hannah RohdjessClinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Melissa HahnClinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Yu-Chan ChihClinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Ling HaiClinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Denise ReiboldClinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Sonja PuschClinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Manuel FischerDepartment of Neuroradiology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Ralph SinnDepartment of Neuroradiology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Dennis Alexander AgardyClinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Dirk Carsten Frieder HoffmannClinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Michael O BreckwoldtDepartment of Neuroradiology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Robin WagenerClinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Leon KaulenClinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Philipp KochCentral Institute of Mental Health, 68159 Mannheim, Germany.
Andreas von DeimlingGerman Cancer Research Center (DKFZ), German Consortium for Translational Cancer Research (DKTK), Clinical Cooperation Unit Neuropathology, 69120 Heidelberg, Germany.
Lukas BunseClinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Michael PlattenClinical Cooperation Unit Neuroimmunology and Brain Tumor Immunology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Felix SahmGerman Cancer Research Center (DKFZ), German Consortium for Translational Cancer Research (DKTK), Clinical Cooperation Unit Neuropathology, 69120 Heidelberg, Germany.
Carsten Müller-TidowMedicine, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Michael SchmittMedicine, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Wolfgang WickClinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Tim SauerMedicine, Hematology, Oncology and Rheumatology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Tobias KesslerClinical Cooperation Unit Neurooncology, German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

CD70, a member of the tumor necrosis factor receptor superfamily, is expressed in glioblastoma (GB), where it promotes tumor growth, migration, and immunosuppression. Accordingly, it has emerged as a target for chimeric antigen receptor (CAR)-T cell therapy. Despite the influence of CAR structure on therapeutic efficacy, no comparative studies have evaluated different CD70-directed CAR designs in GB. Our study addressed this gap. We first validated

Indexed as

CAR-T cellsCD70comparative analysisglioblastomaimmunotherapyMT: Regular Issue

Identifiers

PMID41716471
PMCPMC12915223

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.